Method and composition for preventing or reducing the symptoms of insulin resistance syndrome

Abstract

A method for preventing and or reducing the symptoms of insulin resistance and a related syndrome in persons comprises identifying persons having or at risk for having such symptoms, and administering to them an effective amount of a composition comprising chromium bound niacin that prevents or reduces the symptoms. Compositions incorporating chromium bound niacin and additional compounds also are disclosed that are particularly effective in preventing or reducing these symptoms.

1 . A method for reducing a symptom of syndrome X in a person, the method comprising: 
 (a) identifying a person suffering from or at risk for suffering from the symptom;    (b) administering a composition comprising an effective amount of chromium; and one or more other compounds selected from the group consisting of (−)-hydroxycitric acid, zinc, trans-resveratrol, gymnemic acid, selenium, an anthocyanidin, allicin, and a saponin; and    (c) testing for a reduction in said symptom.    
     
     
         2 . The method of  claim 1 , where in step (c) the symptom is selected from the group consisting of tendency of blood platelets to clot, elevated blood pressure, obesity, central obesity, elevated body mass index, insulin resistance, hyperinsulinemia, hypertension, serum glucose, glucose tolerance, glucose intolerance, lipoprotein lipase deficiency, liver lipid peroxidation, kidney lipid peroxidation, dyslipidemia, hyper-lipidemia, lipid accumulation, elevated triglycerides, reduced high density lipoprotein (HDL), increased low density lipoprotein (LDL) and the LDL to HDL ratio.  
     
     
         3 . The method of  claim 1 , wherein step (b) involves administering the composition in two doses per day.  
     
     
         4 . The method of  claim 1 , wherein said chromium is chromium bound to niacin.  
     
     
         5 . The method of  claim 1 , wherein said other compound is (−)-hydroxycitric acid.  
     
     
         6 . The method of  claim 1 , wherein said other compound is zinc.  
     
     
         7 . The method of  claim 1 , wherein said other compound is trans-resveratrol.  
     
     
         8 . The method of  claim 1 , wherein said other compound is gymnemic acid.  
     
     
         9 . The method of  claim 1 , wherein said other compound is selenium.  
     
     
         10 . The method of  claim 1 , wherein said other compound is an anthocyanidin.  
     
     
         11 . The method of  claim 1 , wherein said other compound is allicin.  
     
     
         12 . The method of  claim 1 , step said other compound is a saponin.  
     
     
         13 . The method of  claim 4 , wherein step (b) involves administering the composition comprising an amount between: 
 about 50 μg; and    about 1000 μg of chromium bound to niacin.    
     
     
         14 . The method of  claim 5 , wherein step (b) involves administering the composition comprising an amount between: 
 about 250 mg; and    about 3000 mg of (−)-hydroxycitric acid.    
     
     
         15 . The method of  claim 6 , wherein step (b) involves administering the composition comprising an amount between: 
 about 5 mg; and    about 50 mg of zinc.    
     
     
         16 . The method of  claim 7 , wherein step (b) involves administering the composition comprising an amount between: 
 about 5 mg; and    about 100 mg of trans-resveratrol.    
     
     
         17 . The method of  claim 8 , wherein step (b) involves administering the composition comprising an amount between: 
 about 50 mg; and    about 200 mg of gymnemic acid.    
     
     
         18 . The method of  claim 9 , wherein step (b) involves administering the composition comprising an amount between: 
 about 0.025 mg; and    about 0.1 mg of selenium.    
     
     
         19 . The method of  claim 10 , step (b) involves administering the composition comprising an amount between: 
 about 5 mg; and    about 100 mg of an anthocyanidin.    
     
     
         20 . The method of  claim 11 , wherein step (b) involves administering the composition comprising an amount between: 
 about 2 mg; and    about 8 mg of allicin.    
     
     
         21 . The method of  claim 12 , wherein step (b) involves administering the composition comprising an amount between: 
 about 100 mg; and    about 300 mg of saponins.    
     
     
         22 . A method for reducing excess liver and/or muscle lipid accumulation comprising: 
 (a) identifying a person suffering from or at risk for suffering from the symptoms;    (b) administering a composition comprising an effective amount of chromium bound niacin, (−)-hydroxycitric acid, gymnemic acid; and one or more other compounds selected from the group consisting of zinc, trans-resveratrol, selenium, an anthocyanidin, allicin, and a saponin; and    (c) testing for a reduction in liver and/or muscle lipid accumulation.